人表皮生长因子受体2阳性肿瘤：癌症研究中一个不断发展的领域
HER-2-Positive Tumors: A Continuously Evolving Field in Cancer Research.
作者信息
Hofheinz Ralf, Lorenzen Sylvie, Bohlmann Michael K
机构信息
Mannheim Cancer Center, University Hospital Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
Klinik und Poliklinik für Innere Medizin III, Technische Universität München, 81675 München, Germany.
出版信息
Cancers (Basel). 2023 Jun 25;15(13):3333. doi: 10.3390/cancers15133333.
Abstract
Almost 25 years ago, trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), was licensed for the treatment of patients with metastatic HER2-positive breast cancer in the United States of America (USA) [...].
摘要
大约25年前，曲妥珠单抗，一种靶向人类表皮生长因子受体2（HER2）的单克隆抗体，在美国被批准用于治疗转移性HER2阳性乳腺癌患者[...]。
相似文献
1
HER-2-Positive Tumors: A Continuously Evolving Field in Cancer Research.人表皮生长因子受体2阳性肿瘤：癌症研究中一个不断发展的领域
Cancers (Basel). 2023 Jun 25;15(13):3333. doi: 10.3390/cancers15133333.
2
A systematic review of dual targeting in HER2-positive breast cancer.HER2 阳性乳腺癌的双重靶向治疗系统评价。
Cancer Treat Rev. 2014 Mar;40(2):259-70. doi: 10.1016/j.ctrv.2013.09.002. Epub 2013 Sep 11.
3
Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab.曲妥珠单抗治疗 HER2 阳性转移性乳腺癌之外的新兴方法。
Ann Oncol. 2013 Oct;24(10):2492-2500. doi: 10.1093/annonc/mdt217. Epub 2013 Jul 4.
4
Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.帕妥珠单抗治疗人表皮生长因子受体 2 阳性转移性乳腺癌。
Am J Health Syst Pharm. 2013 Sep 15;70(18):1579-87. doi: 10.2146/ajhp120735.
6
Therapeutic Strategies for Human Epidermal Receptor-2 Positive Metastatic Breast Cancer: A Literature Review.人表皮生长因子受体2阳性转移性乳腺癌的治疗策略：文献综述
Cureus. 2020 Aug 2;12(8):e9522. doi: 10.7759/cureus.9522.
7
Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.人表皮生长因子受体 2 阳性转移性乳腺癌伴新型表皮生长因子受体-ZNF880 融合和表皮生长因子受体 E114K 突变，吡咯替尼治疗有效：一例报告。
Medicine (Baltimore). 2020 Dec 18;99(51):e23406. doi: 10.1097/MD.0000000000023406.
8
Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.曲妥珠单抗在治疗 HER2 阳性转移性乳腺癌中的应用。
Adv Ther. 2013 Jul;30(7):645-58. doi: 10.1007/s12325-013-0043-2. Epub 2013 Jul 24.
9
Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond.曲妥珠单抗德鲁替康在HER2阳性转移性乳腺癌及其他疾病中的应用
Expert Opin Biol Ther. 2021 Jul;21(7):811-824. doi: 10.1080/14712598.2021.1890710. Epub 2021 Apr 1.
10
Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer.曲妥珠单抗-德鲁替康：在不可切除或转移性 HER2 阳性乳腺癌中的应用评价。
Target Oncol. 2023 May;18(3):463-470. doi: 10.1007/s11523-023-00971-9. Epub 2023 May 2.
引用本文的文献
1
The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts.抗体药物偶联物的伊卡洛斯式飞行：在复杂性中进行靶点选择并应对不良反应
Protein Cell. 2025 Jan 15. doi: 10.1093/procel/pwaf002.
2
Transgenic overexpression of the miR-200b/200a/429 cluster prevents mammary tumor initiation in Neu/Erbb2 transgenic mice.miR-200b/200a/429簇的转基因过表达可预防Neu/Erbb2转基因小鼠发生乳腺肿瘤起始。
Int J Cancer. 2025 Mar 1;156(5):993-1004. doi: 10.1002/ijc.35211. Epub 2024 Oct 6.
本文引用的文献
1
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.图卡替尼联合曲妥珠单抗治疗既往接受过治疗的人表皮生长因子受体 2 阳性转移性胆道癌（SGNTUC-019）：一项 II 期篮子研究。
J Clin Oncol. 2023 Dec 20;41(36):5569-5578. doi: 10.1200/JCO.23.00606. Epub 2023 Sep 26.
2
Interaction between Radiation Therapy and Targeted Therapies in HER2-Positive Breast Cancer: Literature Review, Levels of Evidence for Safety and Recommendations for Optimal Treatment Sequence.人表皮生长因子受体2阳性乳腺癌中放射治疗与靶向治疗的相互作用：文献综述、安全性证据水平及最佳治疗顺序建议
Cancers (Basel). 2023 Apr 13;15(8):2278. doi: 10.3390/cancers15082278.
3
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.图卡替尼联合曲妥珠单抗治疗化疗耐药、HER2 阳性、RAS 野生型不可切除或转移性结直肠癌（MOUNTAINEER）：一项多中心、开放标签、2 期研究。
Lancet Oncol. 2023 May;24(5):496-508. doi: 10.1016/S1470-2045(23)00150-X.
4
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial.曲妥珠单抗联合三联疗法治疗 HER2 过表达的食管腺癌（NRG 肿瘤学/RTOG 1010）：一项多中心、随机、III 期临床试验。
Lancet Oncol. 2022 Feb;23(2):259-269. doi: 10.1016/S1470-2045(21)00718-X. Epub 2022 Jan 14.
5
Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments.人表皮生长因子受体2阳性癌症与基于抗体的治疗：现状与未来发展
Cancers (Basel). 2021 Nov 18;13(22):5771. doi: 10.3390/cancers13225771.
6
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer.免疫标志物与肿瘤相关过程可预测早期乳腺癌WSG-ADAPT HER2阳性/激素受体阳性试验中的新辅助治疗反应。
Cancers (Basel). 2021 Sep 29;13(19):4884. doi: 10.3390/cancers13194884.
7
Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study).曲妥珠单抗和拉帕替尼新辅助诱导双重HER2阻断联合每周一次紫杉醇加双重HER2阻断治疗HER2阳性原发性乳腺癌的随机研究的长期结果（Neo-Lath研究）
Cancers (Basel). 2021 Aug 9;13(16):4008. doi: 10.3390/cancers13164008.
8
Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model.成像引导治疗：曲妥珠单抗和EpCAM导向毒素同时靶向HER2和EpCAM在卵巢癌模型中具有相加作用
Cancers (Basel). 2021 Aug 4;13(16):3939. doi: 10.3390/cancers13163939.
9
HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study.曲妥珠单抗治疗转移性胃癌的疗效及相关影响因素：前瞻性多中心 VARIANZ 研究结果
请注意，这是根据原文进行的直译，可能与实际的医学术语或用法略有差异。在实际应用中，建议根据具体情况进行适当的调整和修正。
J Clin Oncol. 2021 May 1;39(13):1468-1478. doi: 10.1200/JCO.20.02761. Epub 2021 Mar 25.
10
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.曲妥珠单抗-德曲妥珠单抗用于既往治疗的 HER2 阳性胃癌。
N Engl J Med. 2020 Jun 18;382(25):2419-2430. doi: 10.1056/NEJMoa2004413. Epub 2020 May 29.
Zotero 插件